These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10147466)

  • 1. The practical impact of pharmacoeconomics on institutional managers.
    Cooke J
    Pharmacoeconomics; 1994 Oct; 6(4):289-97. PubMed ID: 10147466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacoeconomic impact of compliance].
    Agh T; Mészáros A
    Acta Pharm Hung; 2010; 80(2):75-80. PubMed ID: 20684381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomics--an aid to better decision-making.
    Arenas-Guzman R; Tosti A; Hay R; Haneke E;
    J Eur Acad Dermatol Venereol; 2005 Sep; 19 Suppl 1():34-9. PubMed ID: 16120204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penny and pound wise: pharmacoeconomics from a governmental perspective.
    van Oostenbruggen MF; Jansen RB; Mur K; Kooijman H
    Pharmacoeconomics; 2005; 23(3):219-26. PubMed ID: 15836004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of pharmacoeconomics and pharmaceutical outcomes evaluations.
    Reeder CE
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S5-8. PubMed ID: 8846244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to improve pharmacoeconomic data generalisability between different countries.
    Li SC
    Expert Opin Pharmacother; 2007 Jul; 8(10):1409-13. PubMed ID: 17661723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making.
    Yagudina RI; Kulikov AU; Serpik VG; Ugrekhelidze DT
    Value Health Reg Issues; 2017 Sep; 13():61-66. PubMed ID: 29073991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical economy and the economic assessment of drugs in France.
    le Pen C
    Soc Sci Med; 1997 Aug; 45(4):635-43. PubMed ID: 9226787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Health outcomes analysis and its applications].
    Carrera-Hueso FJ
    Rev Med Univ Navarra; 1997; 41(4):237-44. PubMed ID: 10420964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics and formulary decision making.
    Sanchez LA
    Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomics of appropriate antimicrobial use.
    Davey P
    Diagn Microbiol Infect Dis; 1995; 22(1-2):225-9. PubMed ID: 7587044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacoeconomics in contemporary medicine].
    Czech M
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():16-9. PubMed ID: 15524007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions.
    Tonin FS; Aznar-Lou I; Pontinha VM; Pontarolo R; Fernandez-Llimos F
    Pharm Pract (Granada); 2021; 19(1):2302. PubMed ID: 33727994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of pharmacoeconomics: a commentary.
    Langley PC
    Clin Ther; 1997; 19(4):762-9; discussion 760-1. PubMed ID: 9377619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomics in the new millennium. A pharmaceutical industry perspective.
    Thwaites R; Townsend RJ
    Pharmacoeconomics; 1998 Feb; 13(2):175-80. PubMed ID: 10178645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacoeconomics and cost of cancer drugs].
    Camps Herrero C; Caballero Díaz C; Blasco Cordellat A
    Farm Hosp; 2010 Mar; 34 Suppl 1():12-5. PubMed ID: 20920852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.